KLRSKalaris Therapeutics, Inc.同业对比
Kalaris Therapeutics, Inc. 与SIC 2836 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KLRS本股 | $76M#8 | — | 1.3x#2 | 463.1x#6 | — | 37.2%#3 | -27970.9%#7 | -75.3%#7 | — | — | -27.8%#7 | — |
| BDTX | $112M#3 | — | 1.2x#1 | 1.6x#3 | — | 132.1%#2 | 17.9%#2 | 23276.9%#1 | — | — | -38.4%#10 | — |
| CRDF | $100M#5 | — | 3.8x#7 | 169.2x#5 | -13.2%#3 | -0.9%#5 | -8256.3%#5 | -0.2%#4 | — | — | -35.8%#9 | — |
| ATTO | $1.0B#1 | — | — | — | — | — | — | — | — | — | 310.9%#1 | — |
| ATRA | $100M#6 | — | — | 0.8x#1 | -6.3%#2 | 138.3%#1 | 29.7%#1 | — | — | — | -16.2%#3 | — |
| CGTX | $101M#4 | — | 3.1x#6 | — | — | 30.9%#4 | — | -71.1%#6 | — | — | -27.3%#6 | — |
| ELOX | $75M#9 | 5.2x#1 | 1.6x#3 | — | -100.0%#4 | -90.7%#9 | — | -12.9%#5 | — | — | — | — |
| BSEM | $74M#10 | — | 2.7x#5 | — | — | — | — | 0.0%#2 | — | — | — | — |
| PTHS | $81M#7 | — | — | 4.8x#4 | — | -444.6%#11 | -193.1%#4 | — | — | — | -33.0%#8 | — |
| SCTX | $539M#2 | — | — | — | — | — | — | — | — | — | — | — |
| CSBR | $68M#12 | — | 17.5x#9 | 1.1x#2 | 4.4%#1 | -125.0%#10 | -1.9%#3 | -0.0%#3 | — | — | -26.1%#5 | — |
| LONA | $68M#11 | — | 2.0x#4 | — | — | -9.3%#6 | — | -315.5%#9 | — | — | 93.0%#2 | — |
| EXOZ | $60M#13 | — | 16.5x#8 | 861.0x#7 | — | -56.3%#8 | -13867.0%#6 | -250.6%#8 | — | — | -45.8%#11 | — |
| INKT | $59M#14 | — | — | — | — | -15.9%#7 | — | — | — | — | -19.2%#4 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议